JUVE Patent
About Dr. Eva Ehlich
Eva represents European, US and Japanese companies in the chemical, biochemical and pharmaceutical sectors whom she advises and assists in drafting, prosecuting, defending, enforcing and challenging IP rights in Germany, Europe and worldwide. Along with preparing freedom-to-operate and validity analyses she has experience in patent litigation and strategic patent filing, SPCs, especially in the area of drug delivery, pharmaceutics and medical uses (small molecules and biologics including vaccines) as well as in coordinating international patent portfolios and freedom-to-operate strategies. In this context she coordinates as hub-counsel team-lead large attorney teams including attorneys from Maiwald and international partner law firms.
Eva has received numerous recognitions for her professional activities as a patent attorney.
Dr. Eva Ehlich
Maiwald Intellectual Property
Elisenhof, Elisenstraße 3
80335 Munich
Germany
+49 (0)89 747 266 0
Ehlich@maiwald.eu
3 Specialisms
- Chemistry
- Pharmaceuticals
- Medical Devices
Awards
- Featured among Managing IP’s Top 250 Women in IP 2022
- Recommended in IAM Patent 1000 “World’s Leading Patent Professionals” 2020, 2021, 2022, 2023
- Recommended in Handelsblatt | Best Lawyers "Germany's Best Lawyers" 2019, 2020, 2021, 2022, 2023, 2024
- Recommended in MIP IP Stars 2017, 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Recommended in Legal 500 Deutschland 2017, 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Recommended as one of the world's leading intellectual property strategists by IAM Strategy 300 2021, 2022, 2023, 2024
- Recommend in Legal 500 EMEA 2019, 2020, 2021, 2022, 2023, 2024
- "Frequently recommended lawyer" in the JUVE Handbook of Commercial Law Firms 2017/ 2018, 2017/2018, 2018/2019, 2019/2020, 2020/2021, 2021/2022
- Ranked as "Excellent" in the Leaders League Rankings Germany 2022 and 2023 in the categorie Patent Prosecution, listed as "Leading" in 2024
- "Highly recommended attorney" in JUVE Patent Rankings Germany 2021, 2022, 2023, 2024
- Listed in Who's Who Legal, recommended in the "Germany" and "IP" Ranking 2024
- Listed in IAM Strategy 300 Global Leaders 2022, 2023, 2024, 2025
Sponsored Content
Publications
- Statistics and Takeaways from Continued Application of G 2/21 by the EPO’s Boards of Appeal and First Impressions from the UPC on “Plausibility” epi Information, 1/2025
- After two years of G 2/21 case law, is the interpretation now settling? Managing IP, 2025
- Patenting medical treatments in the US and Europe – a guide for practitioners, Managing IP 2024
- Podcast – Empowering women and nurturing young talent: Maiwald’s commitment to equality and diversity, MIP, 2024
- Is the medical use disclosure standard different for novelty and sufficiency?, Managing IP, 2024
- Interview IAM Strategy 300 Global Leaders, 2024
- JUVE Handbook 2021/2022: Co-publishing article on the topic of „Chancen und Stolpersteine bei Videoverhandlungen am EPA“
- Interview IAM Strategy 300 Global Leaders, 2023
- Maiwald makes the case for patent lawyers to learn something new: LiquidText, The Patent Lawyer (Annual 2024)
- T 0116/18 and a review after 10 months of G 2/21, Managing IP 2024
- Products eligible for the medical use format under the EPC: new insights, Managing IP 2024
- Reliance on a purported technical effect for inventive step – Quo vadis “plausibility” after G 2/21? epi Information, 1/2024
- Promoting women and young talent at MAIWALD, 2024
- „R 0016/13 - A truly positive decision”, epi Information, 03/2015 JUVE Handbook for Commercial Law Firms 2021/2022: "Chances and stumbling blocks in video negotiations at the EPO" (page 787-788) (German only)
- Germany: EBA Set to Hear Case on the Legality of the EPO’s Video Proceedings
- What is Horizon Europe about?
